TG THERAPEUTICS, INC. (TGTX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 799.54M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 140.94M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $799.54M | $140.94M | (m) |
| 2026-03-31 | (m) | $700.35M | $118.68M | (m) |
| 2025-12-31 | (m) | $616.29M | $100.71M | (m) |
| 2025-09-30 | (m) | $531.90M | $77.97M | (m) |
| 2025-06-30 | (m) | $454.07M | $59.22M | (m) |
| 2025-03-31 | (m) | $386.39M | $48.59M | (m) |
| 2024-12-31 | (m) | $329.00M | $38.49M | (m) |
| 2024-09-30 | (m) | $264.79M | $30.94M | (m) |
| 2024-06-30 | (m) | $346.72M | $25.11M | (m) |
| 2024-03-31 | (m) | $289.33M | $18.71M | (m) |
| 2023-12-31 | (m) | $233.66M | $14.13M | (m) |
| 2023-09-30 | (m) | $189.77M | (m) | (m) |
| 2023-06-30 | (m) | $24.05M | (m) | (m) |
| 2023-03-31 | (m) | $8.57M | (m) | (m) |
| 2022-12-31 | (m) | $2.79M | (m) | (m) |
| 2022-09-30 | (m) | $5.03M | (m) | (m) |
| 2022-06-30 | (m) | $6.96M | (m) | (m) |
| 2022-03-31 | (m) | $7.91M | (m) | (m) |
| 2021-12-31 | (m) | $6.69M | (m) | (m) |
| 2021-09-30 | (m) | $4.41M | (m) | (m) |
| 2021-06-30 | (m) | $2.41M | (m) | (m) |
| 2021-03-31 | (m) | $907.00K | (m) | (m) |
| 2020-12-31 | (m) | $152.00K | (m) | (m) |
| 2020-09-30 | (m) | $152.00K | (m) | (m) |
| 2020-06-30 | (m) | $152.00K | (m) | (m) |
| 2020-03-31 | (m) | $152.00K | (m) | (m) |
| 2019-12-31 | (m) | $152.00K | (m) | (m) |
| 2019-09-30 | (m) | $152.00K | (m) | (m) |
| 2019-06-30 | (m) | $152.00K | (m) | (m) |
| 2019-03-31 | (m) | $152.00K | (m) | (m) |
| 2018-12-31 | (m) | $152.00K | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $152.00K | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $152.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |